Immunoblot, Chemiluminescence and ImmunoCap Allergen Specific IgE Evaluation of in Allergic Rhinitis Patients

Immunoblot and Chemiluminescence Assays Versus ImmunoCap: Evaluation of Allergen Specific IgE in Egyptian House Dust Mites Allergic Rhinitis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06137495

Enrollment

Registered

2023-11-18

Start date

2020-12-01

Completion date

2023-06-30

Last updated

2023-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnoses Disease

Brief summary

In the present study the investigators assay house dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard.

Detailed description

All allergic rhinitits patients who were monosensitized to mixed HDMs, identified by SPT, will be subjected to complete history taking and assessment of the inclusion and exclusion criteria, performance of skin prick test and measurement of total serum IgE, measurement of specific IgE by Chemiluminescence Immunoassa, immunoblot assay and ImmunoCAP™ Phadiatop™. The patients will be followed-up for 6 months.

Interventions

DIAGNOSTIC_TESTSensitization to House dust mites

The SPT is performed at the time of diagnosis and after six-months follow-up period. Serum specific IgE is measured by immunoblotting, chemiluminescence, and ImmunoCAP assays

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 50 Years

Healthy volunteers

Inclusion criteria

1. Patient consent. 2. Patient with (18-40) years age known to be allergic rhinitis. 3. Patient with IgE mediated allergic rhinitis (positive total IgE). 4. Patient with positive skin prick testing and monosensitized to HDM

Exclusion criteria

1. Patient refusal 2. Patients taking oral corticosteroid. 3. Patients taking anti-IgE injections. 4. Patients taking intranasal corticosteroid. 5. Patient with non- IgE mediated allergic rhinitis. 6. Patients with chronic diseases.

Design outcomes

Primary

Measure	Time frame	Description
Reduction of serum specific IgE	6 months from diagnosis to end of Follow-up period	Improvement of symptoms and signs of allergy
Conversion of SPT to negative	6 months from diagnosis to end of Follow-up period	Improvement of symptoms and signs of allergy

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026